BR112021016642A2 - Derivados de pirazolopiridina como inibidores de pask - Google Patents
Derivados de pirazolopiridina como inibidores de paskInfo
- Publication number
- BR112021016642A2 BR112021016642A2 BR112021016642A BR112021016642A BR112021016642A2 BR 112021016642 A2 BR112021016642 A2 BR 112021016642A2 BR 112021016642 A BR112021016642 A BR 112021016642A BR 112021016642 A BR112021016642 A BR 112021016642A BR 112021016642 A2 BR112021016642 A2 BR 112021016642A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- pask
- pyrazolopyridine derivatives
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1902490.0A GB201902490D0 (en) | 2019-02-25 | 2019-02-25 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| PCT/EP2020/054122 WO2020173739A1 (en) | 2019-02-25 | 2020-02-17 | Pyrazolopyridine derivatives as inhibitors of pask |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021016642A2 true BR112021016642A2 (pt) | 2021-11-03 |
Family
ID=65998935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021016642A BR112021016642A2 (pt) | 2019-02-25 | 2020-02-17 | Derivados de pirazolopiridina como inibidores de pask |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220144823A1 (https=) |
| EP (1) | EP3931191B1 (https=) |
| JP (1) | JP2022525121A (https=) |
| KR (1) | KR20210134001A (https=) |
| CN (1) | CN113474344A (https=) |
| AR (1) | AR124749A1 (https=) |
| AU (1) | AU2020229041A1 (https=) |
| BR (1) | BR112021016642A2 (https=) |
| CA (1) | CA3130154A1 (https=) |
| CO (1) | CO2021010485A2 (https=) |
| ES (1) | ES2963409T3 (https=) |
| GB (1) | GB201902490D0 (https=) |
| IL (1) | IL285751A (https=) |
| MA (1) | MA55074A (https=) |
| MX (1) | MX2021010093A (https=) |
| PH (1) | PH12021552032A1 (https=) |
| SG (1) | SG11202109157TA (https=) |
| TW (1) | TW202045505A (https=) |
| WO (1) | WO2020173739A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022070288A1 (ja) * | 2020-09-30 | 2022-04-07 | 旭化成ファーマ株式会社 | 含窒素二環化合物 |
| WO2025143152A1 (ja) * | 2023-12-27 | 2025-07-03 | 全薬工業株式会社 | チアゾリル－ピラゾロ［１，５－ａ］ピリジン化合物、およびそのＭＹＬＫ４阻害剤としての使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7074801B1 (en) * | 2001-04-26 | 2006-07-11 | Eisai Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| JP2011530511A (ja) * | 2008-08-05 | 2011-12-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
| WO2010090716A1 (en) * | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
| US10392389B2 (en) * | 2012-10-25 | 2019-08-27 | Bioenergenix Llc | Heterocyclic compounds for the inhibition of PASK |
| CA2969265A1 (en) * | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines and their use |
| EP3615538B1 (en) * | 2017-04-27 | 2024-02-07 | The Brigham and Women's Hospital, Inc. | Novel alk2 inhibitors and methods for inhibiting bmp signaling |
-
2019
- 2019-02-25 GB GBGB1902490.0A patent/GB201902490D0/en not_active Ceased
-
2020
- 2020-02-17 AU AU2020229041A patent/AU2020229041A1/en not_active Abandoned
- 2020-02-17 SG SG11202109157TA patent/SG11202109157TA/en unknown
- 2020-02-17 ES ES20706194T patent/ES2963409T3/es active Active
- 2020-02-17 WO PCT/EP2020/054122 patent/WO2020173739A1/en not_active Ceased
- 2020-02-17 EP EP20706194.6A patent/EP3931191B1/en active Active
- 2020-02-17 CA CA3130154A patent/CA3130154A1/en active Pending
- 2020-02-17 US US17/433,503 patent/US20220144823A1/en not_active Abandoned
- 2020-02-17 BR BR112021016642A patent/BR112021016642A2/pt not_active IP Right Cessation
- 2020-02-17 MX MX2021010093A patent/MX2021010093A/es unknown
- 2020-02-17 PH PH1/2021/552032A patent/PH12021552032A1/en unknown
- 2020-02-17 CN CN202080016700.3A patent/CN113474344A/zh active Pending
- 2020-02-17 MA MA055074A patent/MA55074A/fr unknown
- 2020-02-17 JP JP2021555034A patent/JP2022525121A/ja active Pending
- 2020-02-17 KR KR1020217030814A patent/KR20210134001A/ko not_active Ceased
- 2020-02-21 AR ARP200100485A patent/AR124749A1/es not_active Application Discontinuation
- 2020-02-24 TW TW109105861A patent/TW202045505A/zh unknown
-
2021
- 2021-08-10 CO CONC2021/0010485A patent/CO2021010485A2/es unknown
- 2021-08-22 IL IL285751A patent/IL285751A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3130154A1 (en) | 2020-09-03 |
| TW202045505A (zh) | 2020-12-16 |
| SG11202109157TA (en) | 2021-09-29 |
| MA55074A (fr) | 2022-01-05 |
| ES2963409T3 (es) | 2024-03-27 |
| MX2021010093A (es) | 2021-09-21 |
| KR20210134001A (ko) | 2021-11-08 |
| IL285751A (en) | 2021-10-31 |
| US20220144823A1 (en) | 2022-05-12 |
| PH12021552032A1 (en) | 2022-11-14 |
| AU2020229041A1 (en) | 2021-10-21 |
| WO2020173739A1 (en) | 2020-09-03 |
| EP3931191A1 (en) | 2022-01-05 |
| GB201902490D0 (en) | 2019-04-10 |
| CN113474344A (zh) | 2021-10-01 |
| JP2022525121A (ja) | 2022-05-11 |
| EP3931191B1 (en) | 2023-10-04 |
| CO2021010485A2 (es) | 2021-08-19 |
| AR124749A1 (es) | 2023-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2018005742A (es) | Inhibidores de mcl-1 macrocíclicos para tratar el cáncer | |
| ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| MX2020011085A (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de cinasa pim. | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| BR112017022604A2 (pt) | composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação | |
| CO2018004124A2 (es) | Compuestos heterocíclicos | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| BR112017026132A2 (pt) | piridinas substituídas e métodos de uso | |
| BR112018071408A2 (pt) | “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação | |
| MX2016003486A (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
| BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
| BR112015020350A2 (pt) | derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd | |
| BR112012023421A2 (pt) | composição farmacêutica para tratamento de aumento de pressão intraocular | |
| MX385720B (es) | Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| BR112019007609A2 (pt) | ciclobutano 1,3 di-substituído ou derivados de azetidina como inibidores de sintase de prostaglandina d hematopoiética | |
| MX2018003569A (es) | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. | |
| NI201600014A (es) | Compuestos y composiciones como inhibidores de la mek. | |
| MX2021009806A (es) | Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos. | |
| BR112018011969A2 (pt) | compostos heteroaromáticos como inibidores de btk | |
| SA520412289B1 (ar) | مركبات مثبط الهدف الميكانيكي للراباميسين | |
| BR112017009012A2 (pt) | derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso | |
| CR20170513A (es) | Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap). | |
| BR112016020556A8 (pt) | compostos, composição farmacêutica, método de modulação da atividade do receptor de grelina, método para o tratamento de uma doença e usos de um composto | |
| BR112021016642A2 (pt) | Derivados de pirazolopiridina como inibidores de pask | |
| BR112018076734A2 (pt) | compostos heterocíclicos anti-infecciosos e usos dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |